199 related articles for article (PubMed ID: 29378711)
1. Population Pharmacokinetics of Cefotaxime and Dosage Recommendations in Children with Sickle Cell Disease.
Maksoud E; Koehl B; Facchin A; Ha P; Zhao W; Kaguelidou F; Benkerrou M; Mariani P; Faye A; Lorrot M; Jacqz-Aigrain E
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378711
[TBL] [Abstract][Full Text] [Related]
2. A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants.
Leroux S; Roué JM; Gouyon JB; Biran V; Zheng H; Zhao W; Jacqz-Aigrain E
Antimicrob Agents Chemother; 2016 Nov; 60(11):6626-6634. PubMed ID: 27572399
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetic Model to Optimize Cefotaxime Dosing Regimen in Critically Ill Children.
Béranger A; Oualha M; Urien S; Genuini M; Renolleau S; Aboura R; Hirt D; Heilbronner C; Toubiana J; Tréluyer JM; Benaboud S
Clin Pharmacokinet; 2018 Jul; 57(7):867-875. PubMed ID: 28980166
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.
Nichols K; Chung EK; Knoderer CA; Buenger LE; Healy DP; Dees J; Crumby AS; Kays MB
Antimicrob Agents Chemother; 2016 Jan; 60(1):522-31. PubMed ID: 26552978
[TBL] [Abstract][Full Text] [Related]
5. Variability of ciprofloxacin pharmacokinetics in children: impact on dose range in sickle cell patients.
Facchin A; Bui S; Leroux S; Nacka F; Koehl B; Maksoud E; Fayon M; Jacqz-Aigrain E;
J Antimicrob Chemother; 2018 Dec; 73(12):3423-3429. PubMed ID: 30203024
[TBL] [Abstract][Full Text] [Related]
6. Penetration of Cefotaxime into Cerebrospinal Fluid in Neonates and Young Infants.
Chen XK; Shi HY; Leroux S; Xu HY; Zhou Y; Zheng Y; Huang X; Li Y; Jacqz-Aigrain E; Zhao W
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437625
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of teicoplanin in children.
Ramos-Martín V; Paulus S; Siner S; Scott E; Padmore K; Newland P; Drew RJ; Felton TW; Docobo-Pérez F; Pizer B; Pea F; Peak M; Turner MA; Beresford MW; Hope WW
Antimicrob Agents Chemother; 2014 Nov; 58(11):6920-7. PubMed ID: 25224001
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age.
Zhao W; Hill H; Le Guellec C; Neal T; Mahoney S; Paulus S; Castellan C; Kassai B; van den Anker JN; Kearns GL; Turner MA; Jacqz-Aigrain E;
Antimicrob Agents Chemother; 2014 Nov; 58(11):6572-80. PubMed ID: 25155587
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics and Dosing Optimization of Ceftazidime in Infants.
Shi ZR; Chen XK; Tian LY; Wang YK; Zhang GY; Dong L; Jirasomprasert T; Jacqz-Aigrain E; Zhao W
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378703
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation.
Ahsman MJ; Wildschut ED; Tibboel D; Mathot RA
Antimicrob Agents Chemother; 2010 May; 54(5):1734-41. PubMed ID: 20176908
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics and Dosing Considerations for Gentamicin in Newborns with Suspected or Proven Sepsis Caused by Gram-Negative Bacteria.
Bijleveld YA; van den Heuvel ME; Hodiamont CJ; Mathôt RA; de Haan TR
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795373
[TBL] [Abstract][Full Text] [Related]
12. Target attainment of cefotaxime in critically ill children with meningococcal septic shock as a model for cefotaxime dosing in severe pediatric sepsis.
Hartman SJF; Boeddha NP; Ekinci E; Koch BCP; Donders R; Hazelzet JA; Driessen GJ; de Wildt SN
Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1255-1260. PubMed ID: 30968258
[TBL] [Abstract][Full Text] [Related]
13. Ceftazidime dosage recommendations in burn patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations.
Conil JM; Georges B; Ravat F; Ruiz S; Seguin T; Metsu D; Fourcade O; Saivin S
Clin Ther; 2013 Oct; 35(10):1603-12. PubMed ID: 24094465
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Ampicillin in Neonates with Hypoxemic-Ischemic Encephalopathy in the Setting of Controlled Hypothermia.
Cies JJ; Fugarolas KN; Moore WS; Mason RW; Menkiti OR
Pharmacotherapy; 2017 Apr; 37(4):456-463. PubMed ID: 28226400
[TBL] [Abstract][Full Text] [Related]
15. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients.
Abdel Hadi O; Al Omar S; Nazer LH; Mubarak S; Le J
J Oncol Pharm Pract; 2016 Jun; 22(3):448-53. PubMed ID: 26079639
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics and Dosing Optimization of Vancomycin in Pediatric Liver Transplant Recipients.
Shoji K; Saito J; Nakagawa H; Funaki T; Fukuda A; Sakamoto S; Kasahara M; Momper JD; Capparelli EV; Miyairi I
Microbiol Spectr; 2021 Oct; 9(2):e0046021. PubMed ID: 34612690
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics and Dosing Optimization of Azithromycin in Children with Community-Acquired Pneumonia.
Zheng Y; Liu SP; Xu BP; Shi ZR; Wang K; Yang JB; Huang X; Tang BH; Chen XK; Shi HY; Zhou Y; Wu YE; Qi H; Jacqz-Aigrain E; Shen AD; Zhao W
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941652
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics and Dosing Optimization of Vancomycin in Infants, Children, and Adolescents with Augmented Renal Clearance.
He CY; Ye PP; Liu B; Song L; van den Anker J; Zhao W
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0089721. PubMed ID: 34339268
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics of Doripenem in Pediatric Patients and Monte-Carlo Pharmacokinetic-Pharmacodynamic Simulations for Dosing Regimen Assessment.
Matsuo Y; Ishibashi T; Matsumoto S; Katsube T; Wajima T
J Pharm Sci; 2019 Sep; 108(9):3099-3105. PubMed ID: 30974120
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetic Assessment and Pharmacodynamic Implications of Pediatric Cefepime Dosing for Susceptible-Dose-Dependent Organisms.
Shoji K; Bradley JS; Reed MD; van den Anker JN; Domonoske C; Capparelli EV
Antimicrob Agents Chemother; 2016 Apr; 60(4):2150-6. PubMed ID: 26810655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
